semaglutide type 1 diabetes randomized trial 2024 Effectiveness and Safety of in Diabetes: A Danish Nationwide Cohort Study (2018–2024) Reducing cardiometabolic risk with semaglutide

In a maintenance trial, nausea fell from 47% during escalation to 14% after the 2.4 mg dose was held. Are symptoms not listed on the semaglutide label still reported

I guess most people havent even heard of the most interesting GLP-1 drug in development today

Phase IIb Study of Intranasal Glutathione in Parkinsons Disease

April 19, 2024

This metabolic activity makes visceral fat a frequent measurement point in growth-hormone pathway research, since compounds studied for their effect on endogenous growth hormone release are often evaluated specifically against visceral fat mass rather than total body fat

Tirzepatide may lower blood pressure in some people, especially adults with obesity, excess weight, insulin resistance, or other metabolic health concerns